Two case histories are reported here in which a chemotherapeutic approach i
mproved the clinical conditions of patients with advanced pancreatic cancer
. Until recently, chemotherapy was considered ineffective in pancreatic can
cer, and most oncologists treated these patients with best-supportive-care
only Enthusiasm for systemic therapy of advanced pancreatic cancer is again
growing, spurred by the advent of new drugs and new treatment endpoints su
ch as life quality and symptom palliation. Gemcitabine, the most intensivel
y-investigated new drug in pancreatic cancer: has shown an advantage in bot
h survival and clinical benefit over that of 5-fluorouracil (5-FU). Other n
ew drugs such as taxanes have shown interesting levels of activity, and are
deserving of further evaluation. Although these results are Ear from concl
usive and are only partially satisfactory, they represent a significant ste
p forward in the treatment of advanced pancreatic cancer.